Bioinformatic features and immunological response of recombinant antigen CTLA4-IgV-EgG1Y162 against Echinococcus granulosus
2024

New Vaccine Against Echinococcus granulosus

Sample size: 36 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhao Shangqi, Li Yanmin, Kong Huifang, Zhou Yanxia, Zhou Wentao, Zheng Jia, Gong Qiaoqiao, Cao Chunbao, Ding Jianbing, Zhou Xiaotao

Primary Institution: Xinjiang Medical University

Hypothesis

The recombinant vaccine CTLA-4IgV-EgG1Y162 can enhance immune response against Echinococcus granulosus.

Conclusion

The CTLA-4IgV-EgG1Y162 vaccine shows promise in improving immune responses and could be a valuable candidate for Echinococcus granulosus vaccination.

Supporting Evidence

  • The recombinant vaccine was designed to enhance binding to dendritic cells.
  • CTLA-4IgV-EgG1Y162 promoted maturation of dendritic cells.
  • Immunized mice showed increased levels of protective antibodies.
  • Significant lymphocyte proliferation was observed in response to the vaccine.
  • IL-4 and IFN-γ levels were higher in mice immunized with the new vaccine.

Takeaway

Scientists created a new vaccine that helps the body fight a disease caused by a tiny worm, and it seems to work better than the old one.

Methodology

The study involved creating a recombinant vaccine, testing its effects on dendritic cells and lymphocytes, and measuring immune responses in mice.

Limitations

The immune effect and specificity of the vaccine in intermediate hosts need further verification.

Participant Demographics

Specific pathogen-free C57 and BALB/C mice, aged 6-8 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1590/1414-431X2024e13139

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication